Dr. Philippe Beauclair is a Postdoctoral Researcher in Chemistry at Thryv Therapeutics, where he contributes to the design and synthesis of novel SGK1 inhibitors.

Dr. Beauclair obtained his PhD in Organic Chemistry from the Université de Montréal. His doctoral research focused on developing transmembrane chloride transporters that disrupt cellular homeostasis, exploring their potential as a therapy for cystic fibrosis.